With Janssen Biotech Inc.’s one-shot COVID vaccine set for review by the US FDA’s Vaccines and Related Biologics Products Advisory Committee on 26 February, the sponsor and agency have a chance to learn from some of the shortcomings of the panel’s meetings last year.
FDA had a lot of practice conducting virtual meetings in the run up to the two historic and likely most...





